“And so the similar would have happened, we believe, with evacetrapib in the Accelerate trial. Although with Repatha and Pralulin, we did see benefit at about two years. This was only a 15% LDL lowering. Yeah, yeah, yeah, yeah, yeah. So it's also interesting in the Odyssey outcome study, which is the Pralulin, which is the other PCSCAT inhibitor, if you look”
“Amgen had put it on the shelf because Repatha had struggled on its launch. They deprioritized it. So they kind of had it sitting there ready to go into phase two, maybe even right into phase three potentially.”
“I might switch to a PCSK9 inhibitor because it's more effective, but my family is very high class. I'm on Repatha. Great. Yeah. You like it? I've actually stopped taking Repatha because I want to see if it's causing some brain fog. Oh, that is sometimes associated.”